Moyamoya Disease Suzuki Stage III in Adult: Diagnosis and Conservative Management - A Case Report

Case Report

Authors

  • Ni Made Ayu Candrayuni Resident Medical Officer, Siloam Hospitals Bali, Badung, Indonesia
  • Marsya Julia Riyadi Resident Medical Officer, Bali Royal Hospital, Denpasar, Indonesia
  • I Made Edwin Alberty Wardhana Resident Medical Officer, Siloam Hospitals Bali, Badung, Indonesia

DOI:

https://doi.org/10.55175/cdk.v53i06.1980

Keywords:

Case report, cerebrovascular, Moyamoya disease, Suzuki stage III, ischemic stroke

Abstract

Introduction: Moyamoya disease (MMD) is a rare, progressive cerebrovascular condition, predisposing patients to ischemic or hemorrhagic strokes—particularly among Asian populations. Case: A 38-year-old male with a prior ischemic stroke in 2023 presented with acute left lower limb weakness lasting two days. MRI showed an acute and chronic ischemic lesion, and an acute lacunar infarct in the right superior frontal gyrus. MRA and cerebral angiography confirmed Suzuki stage III MMD, with A1 right anterior cerebral artery (ACA) occlusion and collateral flow from the left posterior cerebral artery (PCA). Cerebral angiography revealed occlusion of the proximal A1 segment of the right ACA and a characteristic “puff of smoke” appearance from abnormal collateral vessels in the distal branches of the right middle cerebral artery (MCA). The patient was managed conservatively with cilostazol, rosuvastatin, and antiplatelet therapy, alongside physical rehabilitation, resulting in functional improvement. Discussion: MMD is a progressive vasculopathy that may cause recurrent cerebrovascular events due to impaired cerebral perfusion. Cerebral angiography remains essential for diagnosis and Suzuki staging. Although revascularization surgery is the standard treatment to improve cerebral blood flow and reduce stroke risk, conservative management may be considered in selected patients based on clinical stability, collateral circulation, and treatment indications. In this case, conservative therapy combined with rehabilitation was associated with clinical improvement, although continuous monitoring is required due to the progressive nature of the disease. Conclusion: Early diagnosis of MMD through advanced neuroimaging is crucial for preventing recurrent stroke and guiding treatment decisions. This case highlights that individualized conservative management may provide clinical benefits in adult Suzuki stage III MMD when surgical intervention is not immediately performed, while long-term follow-up remains essential.

Downloads

Download data is not yet available.

References

Kustila E, Pasaribu C. Acute ischemic stroke in moyamoya disease: a case report. Acta Neurologica Indonesia 2024;02(02):46–9. https://doi.org/10.69868/ani.v2i02.30.

Strunk D, Bauer P, Keyvani K, Diehl RR, Veltkamp R, Berlit P, et al. Moyamoya disease in Southeast Asians: genetic and autopsy data, new cases, systematic review, and meta-analysis of all patients from the literature. J Neurol 2024;271:3328–39. doi: 10.1007/s00415-024-12228-0.

Muljadi R, Koesbandono, Pratama T, Octavius GS. Moyamoya disease and moyamoya syndrome: a case series from multicentre private hospitals in Indonesia. Neurocirugia. 2025;36:151–60. doi: 10.1016/j.neucie.2024.11.008.

Zhang Y, Zhang L, Zhang X, Zhang Y, Zhang J, Zhang Y, et al. Increase in Age at Onset of Moyamoya Disease in China over 25 Years. Neurol Med Chir (Tokyo). 2023;63(1):1–7. doi:10.2176/jns-nmc.2022-0382.

Safiani M, Bennasser A, Ajerame A, Halfi I, Jiddane M, Touarsa F. Ischemic stroke in a young adult revealing moyamoya disease: a rare cause. Internat J Advanced Res. 2025;13(03):107–11. doi: 10.21474/IJAR01/20542.

Fang JX, Yang XZ, Ni J. RNF213 in moyamoya disease: genotype-phenotype association and the underlying mechanism. Chin Med J (Engl). 2024;137(21):2552–60. doi:10.1097/CM9.0000000000002985.

Wang X, Zhang Z, Liu W, Xiong Y, Sun W, Huang X, et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of moyamoya disease in Han Chinese human subjects. Gene. 2013;526(2):437–442. doi:10.1016/j.gene.2013.05.083.

Martens R, Graupera M, Gerhardt H, Bersano A, Tournier-Lasserve E, Mensah MA, et al. The genetic basis of moyamoya disease. Transl Stroke Res. 2022;13:25–45. doi: 10.1007/s12975-021-00940-2.

Ishiyama H, Ihara M. Eur J Hum Genet. 2023;31(7):733-4. doi: 10.1038/s41431-023-01353-5.

Luo Y, Cao Z, Wu S, Sun X. Ring finger protein 213 in moyamoya disease with pulmonary arterial hypertension: a mini-review. Front Neurol. 2022;13:843927. doi:10.3389/fneur.2022.843927.

Yamamoto K, Kaku Y, Koga H. Case report: RNF213 variant and choroidal anastomosis as potential risk factors for early stroke in moyamoya syndrome associated with Down syndrome. Front Pediatr. 2023;11:1289554. doi:10.3389/fped.2023.1289554.

Fujimura M, Tominaga T, Kuroda S, Takahashi JC, Endo H, Ogasawara K, et al. 2021 Japanese guidelines for the management of moyamoya disease: guidelines from the Research Committee on moyamoya disease and Japan Stroke Society. Neurol Med Chir (Tokyo). 2022;62(4):165–70. doi: 10.2176/jns-nmc.2021-0382.

Yamada S, Oki K, Itoh Y, Kuroda S, Houkin K, Tominaga T, et al. Effects of surgery and antiplatelet therapy in ten-year follow-up from the Registry Study of Research Committee on Moyamoya Disease in Japan. J Stroke Cerebrovasc Dis. 2016;25(2):340–9. doi: 10.1016/j.jstrokecerebrovasdis.2015.10.003.

He S, Zhou Z, Cheng MY, Hao X, Chiang T, Wang Y, et al. Advances in moyamoya disease: pathogenesis, diagnosis, and therapeutic interventions. MedComm. 2025;6:e70054. doi: 10.1002/mco2.70054.

Yu S, Zhang N, Liu J, Li C, Qian S, Xu Y, et al. Surgical revascularization vs. conservative treatment for adult hemorrhagic moyamoya disease: analysis of rebleeding in 322 consecutive patients. Neurosurg Rev. 2022;45(2):1709–20. doi:10.1007/s10143-021-01689-w.

Wang Y, Li M, Wang J. Indirect revascularization vs. non-surgical treatment for moyamoya disease and moyamoya syndrome: a comparative effectiveness study. Front Neurol. 2022;13:1041886. doi: 10.3389/fneur.2022.1041886.

Teo CKA, Zhen Y, Lin JB, Teoh HL, Chan BPL, Sharma VK, et al. Outcomes after surgical revascularization for adult Moyamoya disease: a Southeast Asian tertiary centre experience. J Clin Neurosci. 2024;119:116-21. doi: 10.1016/j.jocn.2023.11.027.

Shahbandi A, Sattari SA, Azad TD, Xia Y, Lehner K, Yang W, et al. The management of symptomatic moyamoya disease in pediatric patients: a systematic review and meta-analysis. Neurosurgery 2024;97(1):65-81. doi: 10.1227/neu.0000000000003277.

Kurisu K, Ito M, Uchino H, Sugiyama T, Fujimura M. Long-term outcomes of combined revascularization surgery for moyamoya disease in the elderly: a single institute experience. Neurol Med Chir (Tokyo). 2024;64(3):108–15. doi:10.2176/jns-nmc.2023-0219.

Downloads

Published

15-06-2026

How to Cite

Candrayuni, N. M. A., Riyadi, M. J., & Wardhana, I. M. E. A. (2026). Moyamoya Disease Suzuki Stage III in Adult: Diagnosis and Conservative Management - A Case Report: Case Report. Cermin Dunia Kedokteran, 53(06), 401–405. https://doi.org/10.55175/cdk.v53i06.1980

Issue

Section

Articles